Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 04/02/15 -- Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this , Daniel N. Swisher Jr., president and CEO of (NASDAQ: SNSS), describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors.
Daniel, Sunesis Pharmaceuticals Inc. has been around for more than 15 years. How does the Sunesis of today compare to its pioneering days?
Sunesis was formed in 1998 with an initial focus on new discovery tools for small molecule drugs to address significant unmet needs. Since then, we've become a late-stage development and pre-commercial company focused on oncology, thus leveraging our pioneering tyrosine kinase work. In addition, we acquired worldwide rights for vosaroxin, our lead development product. What has remained constant is our strong focus on high-quality science and innovation.
Has your program evolution been a result of changes in managerial interests over the years?
I'd say our evolution has been driven primarily by shifting from a laboratory-focused, early science-based company to an integrated pre-commercial oncology company...
Continue reading this interview with Daniel Swisher:
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.
Sunesis Pharmaceuticals Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. David Swisher had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of David Swisher and not of The Life Sciences Report or its officers.
Brandon Fung
Tel: 707-981-8107
Email:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.04.2015 - 18:33 Uhr
Sprache: Deutsch
News-ID 383281
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Alternative
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sunesis Pharmaceuticals Inc.'s CEO Daniel Swisher Interviewed by The Life Sciences Report"
steht unter der journalistisch-redaktionellen Verantwortung von
Streetwise Reports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
